Luas Diagnostics partners with Bond Digital Health to provide 15-minute Covid-19 Immune Status Test with smartphone app and data management software

 Luas Diagnostics partners with Bond Digital Health to provide 15-minute Covid-19 Immune Status Test with smartphone app and data management software

 

Luas Diagnostics of Guildford, Surrey, today announced the launch of their enhanced test to determine immunity to Covid-19 post infection or vaccination. The upgraded offering follows the development of a smartphone app and data management software specific to the Luas product, by Bond Digital Health.

 

The Immunity Test, which is manufactured by Chembio Diagnostics Systems of New York, uses a fingerstick of blood for the detection, differentiation and quantification of IgM and IgG receptor binding domain antibodies to SARS-CoV-2. The results are read and stored in a portable reader which provides semi-quantitative results in either laboratory or remote settings. The total time to result is 15 minutes.

 

The Luas Diagnostics app, which is available now in the Google Play store and the Apple App store, is powered by Transform®, a lateral flow data capture platform developed by Bond Digital Health. The smartphone app provides a personalised, printable and shareable antibody report and the associated dashboard manages testing, recording and reporting of results in real time at single or multiple locations.

 

Brendan Farrell, CEO of Luas Diagnostics, commented: “We are excited to work together with Bond Digital Health to provide a comprehensive Immunity Test offering with applications in many locations including the workplace, in-store testing, care homes and GP surgeries. A recent study has shown that 10-15% of people, particularly among the higher age group, may not produce antibodies even after the second dose of vaccine and thus may have limited protection against the virus. This emphasises the need for individuals to understand their immunity status through regular testing.”

 

Ian Smith, CEO of Bond Digital Health, said: “Antibody testing is the next tool we should be using in the fight against Covid-19. That’s why we are proud to partner with Luas on their vital Immunity Test. But testing alone isn’t enough. Whether in workplaces, care homes, GP surgeries or in the community, we need to capture the test data, store it securely and share it to make sure we have a complete picture of immunity. The Luas App, powered by Transform®, does just that.”

 

www.luasdiagnostics.com /

 

ends

 

 

 

Notes to editors

 

About Luas Diagnostics

 

Luas Diagnostics is based in Guildford, Surrey and is a UK registered private company, which was founded in 2020.

 

Luas is specialised in the development, manufacture and marketing of rapid tests which can be used Point-of-Care and which are e-health enabled. The focus of our R+D is on the development of rapid, quantitative tests to determine the levels of therapeutic drugs in a patients’ blood using a hand-held reader which transmits the results to a secure cloud for access by physicians.

In addition, we are the exclusive distributor in the UK and Ireland of the Chembio Diagnostic Systems Point-of-care products for infectious diseases

www.luasdiagnostics.com /

 

About Bond Digital Health

Based in Cardiff, UK, Bond Digital Health Ltd is the only company in the world offering bespoke digital products and services specifically for lateral flow devices. Bond is digitising an entire industry and helping with global efforts to decentralise health testing. Bond has developed a white label digital platform for lateral flow technologies, called Transform®. Featuring app development, cloud data management and a real-time analytics dashboard, Transform® offers secure cloud connectivity and is fully regulated and compliant with medical device software regulations.

www.bondhealth.co.uk

 

About Chembio Diagnostic Systems

Chembio Diagnostics Systems of Hauppauge New York is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners.

 

The DPP Covid-19 IgM/IgG test, which is CE marked, uses fingerstick whole blood to produce a result in 15 minutes and separately and simultaneously detects both the IgM and IgG antibodies to Sars-CoV-2, thus providing a result showing whether the patient has been infected and whether it is a current or past infection.

 

Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Other products in the Chembio portfolio include Point-of-Care tests for HIV (oral fluid and blood), Syphilis, Zika virus and Ebola.

 

For further information and images, please contact:

johnstarr@clareville.co.uk

tel 07860 200934

Share this story

Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn